Echocardiography (Mount Kisco, N.Y.) · 2026
Efficacy Evaluation of Right-Heart Contrast Echocardiography Combined With the Valsalva Manoeuvre in Screening for Patent Foramen Ovale in Patients With Migraine Without an Identified Secondary Cause.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gu Haijuan, Xia Jiesheng, Xu Zhenhua, Shi Jianwei
Аннотация
OBJECTIVE: This study aimed to validate the efficacy of right-heart contrast echocardiography (RHCE) combined with the Valsalva manoeuvre for screening for patent foramen ovale (PFO) in patients with migraine without an identified secondary cause.
METHODS: We enrolled 232 patients between April 2023 and December 2024. All underwent RHCE with a standardized Valsalva manoeuvre, using transoesophageal echocardiography (TEE) as the reference standard. Diagnostic performance, consistency and correlations were analyzed. A major methodological limitation of this study was that intrathoracic pressure during the Valsalva manoeuvre was not quantitatively measured.
RESULTS: The PFO-positive rate was 61.64% (143/232). Using TEE as the reference standard, the sensitivity was 92.03%, the specificity was 85.14%, the accuracy was 89.22% and the area under the curve was 0.886 (95% confidence interval: 0.841-0.931). Discordant results occurred in 26 patients. The prevalence of PFO was significantly higher in patients with migraine with aura than in those without aura (70.59% vs. 54.72%, p < 0.05).
CONCLUSION: Right-heart contrast echocardiography combined with the Valsalva manoeuvre is a non-invasive, convenient and effective method for PFO screening in patients with migraine without an identified secondary cause, especially those with aura.
METHODS: We enrolled 232 patients between April 2023 and December 2024. All underwent RHCE with a standardized Valsalva manoeuvre, using transoesophageal echocardiography (TEE) as the reference standard. Diagnostic performance, consistency and correlations were analyzed. A major methodological limitation of this study was that intrathoracic pressure during the Valsalva manoeuvre was not quantitatively measured.
RESULTS: The PFO-positive rate was 61.64% (143/232). Using TEE as the reference standard, the sensitivity was 92.03%, the specificity was 85.14%, the accuracy was 89.22% and the area under the curve was 0.886 (95% confidence interval: 0.841-0.931). Discordant results occurred in 26 patients. The prevalence of PFO was significantly higher in patients with migraine with aura than in those without aura (70.59% vs. 54.72%, p < 0.05).
CONCLUSION: Right-heart contrast echocardiography combined with the Valsalva manoeuvre is a non-invasive, convenient and effective method for PFO screening in patients with migraine without an identified secondary cause, especially those with aura.